LYEL Stock Summary and Trading Ideas (Lyell Immunopharma | NASDAQ:LYEL)

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

What symbol and exchange does Lyell Immunopharma shares trade?

Lyell Immunopharma trades on the NASDAQ stock market under the symbol LYEL.

What is Lyell Immunopharma stock price doing today?

As of June 5, 2026, LYEL stock price declined to $11.97 with 95,837 million shares trading.

What is Lyell Immunopharma's Beta?

LYEL has a beta of 3.06, meaning it tends to be more sensitive to market movements. LYEL has a correlation of 0.14 to the broad based SPY ETF.

How much is Lyell Immunopharma worth?

LYEL has a market cap of $279.29 million. This is considered a Small Cap stock.

How much money does Lyell Immunopharma make?

Last quarter Lyell Immunopharma reported $2,000 in Revenue and -$1.10 earnings per share. This fell short of revenue expectation by $-2,400 and exceeded earnings estimates by $1.35.

What is the highest and lowest price Lyell Immunopharma traded in the last 3 year period?

In the last 3 years, LYEL traded as high as $79.40 and as low as $7.65.

What are the top ETFs holding Lyell Immunopharma?

The top ETF exchange traded funds that LYEL belongs to (by Net Assets): VTI, VXF, SCHA, IBB, VHT.

Is Lyell Immunopharma (LYEL) a good investment?

LYEL has underperformed the market in the last year with a price return of +4.5% while the SPY ETF gained +25.6%. LYEL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -45.7% and -31.4%, respectively, while the SPY returned +8.5% and -1.1%, respectively.

What are the support and resistance levels for Lyell Immunopharma (LYEL)?

LYEL support price is $12.22 and resistance is $13.88 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LYEL shares will trade within this expected range on the day.